SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is trending amidst community discussions surrounding the potential rescheduling of cannabis and upcoming policy deadlines for hemp products, with enthusiasts highlighting its role as a culture-first cryptocurrency on Solana ahead of the 4/20 period. The narrative emphasizes its alignment with the broader cannabis movement and a long-term, patient investment approach.

iShares Trust - iShares 0-3 Month Treasury Bond ETF

iShares 0-3 Month Treasury Bond ETF

Investors are increasingly turning to SGOV, the iShares 0-3 Month Treasury Bond ETF, as a secure 'cash parking' strategy amid broader market uncertainty and anticipation of a potential pullback. The community is actively touting its attractive 4-5% monthly yield and state tax exemption as a preferred low-risk alternative to traditional savings accounts and higher-volatility assets.

SSgA Active Trust - State Street Materials Select Sector SPDR ETF

Materials Select Sector SPDR Fund

Materials Select Sector SPDR Fund (XLB) is gaining significant attention following recent tariff announcements on key minerals like copper and Chinese graphite, which are seen as inflationary catalysts boosting domestic production. The community is actively discussing a broader market rotation into materials as an undervalued cyclical sector and inflation hedge, with many anticipating further upside despite some calls for consolidation.

SSgA Active Trust - State Street Industrial Select Sector SPDR ETF

Industrial Select Sector SPDR Fund

The Industrial Select Sector SPDR Fund (XLI) is trending as the community highlights its strong technical structure and leadership amid broader market rotation, fueled by impressive industrial earnings and a positive outlook for manufacturing activity.

SSgA Active Trust - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing investor attention amid a noticeable sector rotation away from technology and into areas like energy and defensive stocks. This shift is amplified by varied earnings reports from major tech components and ongoing concerns within the community about the sustainability of AI-driven growth and high capital expenditures.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is drawing significant community discussion propelled by high-visibility marketing on the Las Vegas Sphere and new partnerships with brands like the NHL, fueling anticipation for its expanding real-world utility amid fluctuating meme coin sentiment.

SSgA Active Trust - State Street Utilities Select Sector SPDR ETF

Utilities Select Sector SPDR Fund

The Utilities Select Sector SPDR Fund (XLU) is trending as a dual play, offering investors a defensive haven amid market uncertainty while also being a direct beneficiary of surging electricity demand from AI data centers. This dynamic is driving its strong price momentum, prompting community discussion on whether the sector's current valuation is sustainable or becoming overextended.

Alimentation-Couche Tard, Inc.

Alimentation Couche-Tard is trending as community sentiment shifts from prolonged frustration to renewed optimism following the withdrawal of its major acquisition bid. Many now view the removal of this potential overhang as a catalyst for the convenience store giant to finally "awaken" and break out beyond stagnant trading ranges.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is trending following an oversubscribed $53 million private placement from leading healthcare institutional investors, coupled with promising Phase 1b trial data for its FB102 candidate in celiac disease. The community is actively debating the stock's potential for a significant rally due to the low float and strong institutional backing, amidst discussions of past volatility and potential dilution.

Rapid7, Inc. engages in the provision of cyber security analytics and automation services. Its products include Metasploit, Nexpose, AppSpider, tCell by Rapid7, as well as insight platforms such as InsightDR, InsightIVM, InsightAppSec, InsightConnect, and InsightOps. The firm also offers security and product consulting services. The company was founded by Alan P. Matthews, Tas Giakouminakis, and Chad Loder in July 2000 and is headquartered in Boston, MA.

Rapid7 Inc

A recent sharp stock decline, driven by analyst downgrades and cautious forward guidance, has Rapid7 Inc. trending as investors debate its valuation. The community is actively discussing the potential for a private equity buyout, spurred by activist investor interest and high institutional ownership, viewing it as a deep value play in the consolidating cybersecurity sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

Equity

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.

Lipella Pharmaceuticals Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$0.192
Prev Close	$0.19
Open	$0.165
Dividend Yield	0.00%
50-Day Moving Average	$0.218
Beta	0.63
Avg. Volume	3,236.05
PE Ratio	-0.08

52-Week High	$3.89
52-Week Low	$0.165
Market Capitalization	$887,201.00
EPS (Annual)	-$4.79
Price to Book	0.60
Revenue Per Employee	$76,622.43

LIPO
Lipella Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest LIPO News

LIPOLipella Pharmaceuticals Inc